Opus Genetics, Inc.
NASDAQ: IRD · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-03
Opus Genetics, Inc. (IRD) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | $1.78M | $17.68M | $26.08M | $48.99M | $53.95M | $36.86M | $50.24M |
| Cash & equivalents | $1.54M | $16.40M | $24.53M | $42.63M | $50.50M | $30.32M | $45.09M |
| Current assets | $1.76M | $17.67M | $26.07M | $48.99M | $53.95M | $36.61M | $50.04M |
| Total liabilities | $9.34M | $31.15M | $3.85M | $2.75M | $4.04M | $30.14M | $34.90M |
| Current liabilities | $9.34M | $3.19M | $3.85M | $2.75M | $4.04M | $11.29M | $7.78M |
| Long-term debt | — | — | — | — | — | — | $1.13M |
| Shareholder equity | $-7.56M | $-13.47M | $22.22M | $46.24M | $49.91M | $6.72M | $15.35M |
| Retained earnings | $-8.05M | $-32.67M | $-89.37M | $-71.48M | $-81.47M | $-139.00M | $-188.59M |
| Accounts receivable | $125000.00 | — | $0.00 | $4.85M | $2.33M | $5.77M | $3.17M |
| Inventory | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — |
Frequently asked questions
What is Opus Genetics, Inc.'s revenue?
Opus Genetics, Inc.'s trailing twelve-month revenue is $11.98M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is IRD?
In its most recent fiscal year, IRD ran a gross margin of 100.00%, an operating margin of -271.90%, and a net margin of -349.33%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does IRD generate?
IRD produced $-35.25M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is IRD's balance sheet healthy?
IRD holds $45.09M in cash and equivalents against $1.13M in long-term debt, on $15.35M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.